Peer-reviewed veterinary case report
Carboplatin alone extends cancer-free time after dog leg bone cancer
By Skorupski, K A et al.·Published in Veterinary and comparative oncology·2016·Department of Veterinary Surgical and Radiological Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
- Species:
- dog
Plain-English summary
A group of dogs with bone cancer in their legs (appendicular osteosarcoma) underwent surgery to remove the affected limb and then received different chemotherapy treatments. Some dogs were given six doses of carboplatin, while others received three doses of carboplatin and three doses of doxorubicin in an alternating schedule. The dogs that received only carboplatin had a longer period without cancer recurrence, lasting about 425 days compared to 135 days for those on the alternating treatment. Both treatments had similar side effects, but carboplatin alone appeared to be more effective in delaying the return of cancer.
People also search for: dog osteosarcoma treatment · carboplatin for dogs · doxorubicin side effects in dogs
Abstract
Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin (P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24118677/